Moreover, the absence of a CABG arm in REVIVED, along with advancements in contemporary HF treatments such as angiotensin receptor-neprilysin inhibitors (ARNI) and SGLT2 (sodium–glucose cotransporter 2)-inhibitors, underscores the need for updated studies [56,57]. The gene discussed is SLC5A2; the disease is hydrops fetalis.